Skip to ContentGo to accessibility pageKeyboard shortcuts menu
OpenStax Logo
Pharmacology for Nurses

36.7 Phosphodiesterase 5 Inhibitors

Pharmacology for Nurses36.7 Phosphodiesterase 5 Inhibitors

Learning Outcomes

By the end of this section, you should be able to:

  • 36.7.1 Identify the characteristics of phosphodiesterase 5 inhibitor drugs used to treat erectile dysfunction.
  • 36.7.2 Explain the indications, actions, adverse reactions, and interactions of phosphodiesterase 5 inhibitor drugs used to treat erectile dysfunction.
  • 36.7.3 Describe nursing implications of phosphodiesterase 5 inhibitor drugs used to treat erectile dysfunction.
  • 36.7.4 Explain the client education related to phosphodiesterase 5 inhibitor drugs used to treat erectile dysfunction.

Phosphodiesterase 5 (PDE5) inhibitors are used to treat erectile dysfunction. PDE5 is an enzyme located within the walls of blood vessels that impacts blood flow. PDE5 inhibitors prevent the PDE5 enzyme from functioning, which results in the relaxation of the blood vessels and increased blood flow. PDE5 inhibitors work in cases when blood flow to the corpus cavernosum is inadequate, such as in aging or due to vascular or neurological problems. However, these medications cannot be used for every cause of erectile dysfunction, and they do have serious side effects if taken incorrectly, such as taking more than one dose in 24 hours or taking with nitroglycerin. Sildenafil, tadalafil, avanafil, and vardenafil are the common PDE inhibitors. (Use of PDE5 inhibitors for treating benign prostatic hyperplasia is discussed in Urinary and Bladder Disorder Drugs).

Table 36.24 lists common PDE5 inhibitors and typical routes and dosing for adult clients.

Drug Routes and Dosage Ranges
Sildenafil
(Viagra)
50 mg orally, as needed, approximately 60 minutes before sexual activity.
Dose range: 25–100 mg. Maximum of 1 dose/day.
Tadalafil
(Cialis)
10 mg orally, as needed, approximately 60 minutes before sexual activity. Dose range: 5–20 mg. Maximum of 1 dose/day.
Avanafil
(Stendra)
100 mg orally, as needed, as early as approximately 15 minutes before sexual activity.
Dose range: 50–200 mg. Maximum of 1 dose/day.
Vardenafil
(Levitra)
10 mg orally, as needed, approximately 60 minutes before sexual activity. Dose range: 5–20 mg. Maximum of 1 dose/day.
Table 36.24 Drug Emphasis Table: Phosphodiesterase 5 Inhibitors (source: https://dailymed.nlm.nih.gov/dailymed/)

Adverse Effects and Contraindications

Contraindications for PDE5 inhibitors include the concomitant use of nitrates or alpha-adrenergic blockers, medications often prescribed for cardiovascular problems. The drug interaction can cause life-threatening hypotension and death. Another contraindication is any obstructive condition or anatomical deformation of the penis (DailyMed, Viagra, 2019; Dhaliwal & Gupta, 2023).

Table 36.25 is a drug prototype table for PDE5 inhibitors featuring sildenafil. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

Drug Class
Phosphodiesterase 5 inhibitor

Mechanism of Action
Smooth muscle relaxation and inflow of blood to the corpus cavernosum
Drug Dosage
50 mg orally, as needed, approximately 1 hour before sexual activity.
Dose range: 25–100 mg. Maximum of 1 dose/day.
Indications
Male erectile dysfunction

Therapeutic Effects
Enhanced penile erection
Drug Interactions
Nitrates (all forms)
Alpha blockers
Strong CYP3A4 inhibitors

Food Interactions
No significant interactions
Adverse Effects
Headaches
Flushing
Symptoms resembling those of the common cold
Stomach upset
Muscle and back pain
Dizziness, lightheadedness
Nausea
Abnormal vision
Nasal congestion
Contraindications
Known hypersensitivity to the drug or its components

Caution:
History of heart attack, heart failure, angina, severe arrhythmia, or stroke in the last 6 months
Hypotension or hypertension (resting BP <90/50 mm Hg or BP >170/110 mm Hg)
Hepatic impairment
Severe renal impairment
Anatomical deformation of the penis
Table 36.25 Drug Prototype Table: Sildenafil (source: https://dailymed.nlm.nih.gov/dailymed/)

Nursing Implications

The nurse should do the following for clients who are taking phosphodiesterase 5 inhibitors:

  • Assess understanding of indication for specific drug therapy and ability to comprehend instructions.
  • Perform physical assessment as appropriate and obtain any diagnostic testing necessary.
  • Obtain list of current medications and any OTC or herbal remedies the client uses, especially regarding nitrates and alpha blockers.
  • Assess past medical history and family history for cardiovascular disease (heart attack, stroke, hypertension, serious arrhythmias), prostate cancer, BPH, and liver or renal disease.
  • Assess smoking history and use of alcohol.
  • Assess ability to administer drug at home and follow medication regimen.
  • Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.

Client Teaching Guidelines

The client taking a phosphodiesterase 5 inhibitor should:

  • Understand the medication’s purpose, side effects, contraindications, and precautions.
  • Monitor any signs and symptoms of adverse effects and report those that require immediate attention (e.g., vision or hearing loss, priapism).
  • Know how to manage the side effects of the specific drug therapy.
  • Understand drug, food, and/or herbal interactions that could be harmful.
  • Verbalize the importance of follow-up appointments to manage the medication regimen and to observe for adverse effects.

The client taking a phosphodiesterase 5 inhibitor should not:

  • Take nitrates and alpha blockers within 48 hours of taking PDE5 inhibitors.
  • Take these medications after a high-fat meal.

FDA Black Box Warning

Phosphodiesterase 5 (PDE5) Inhibitors

PDE5 inhibitors can cause:

  • Severe hypotension and death when used within 48 hours of any form of nitrate medication
  • Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration)
  • Sudden loss of vision in one or both eyes (may be a sign of nonarteritic anterior ischemic optic neuropathy)
  • Sudden decrease in or loss of hearing
Citation/Attribution

This book may not be used in the training of large language models or otherwise be ingested into large language models or generative AI offerings without OpenStax's permission.

Want to cite, share, or modify this book? This book uses the Creative Commons Attribution License and you must attribute OpenStax.

Attribution information
  • If you are redistributing all or part of this book in a print format, then you must include on every physical page the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
  • If you are redistributing all or part of this book in a digital format, then you must include on every digital page view the following attribution:
    Access for free at https://openstax.org/books/pharmacology/pages/1-introduction
Citation information

© May 15, 2024 OpenStax. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution License . The OpenStax name, OpenStax logo, OpenStax book covers, OpenStax CNX name, and OpenStax CNX logo are not subject to the Creative Commons license and may not be reproduced without the prior and express written consent of Rice University.